Home › NDC Lookup › RxCUI directory › RxCUI 2001319

Roflumilast 0.25 MG Oral Tablet — RxCUI 2001319

RxNorm drug concept · Semantic clinical drug
RxCUI 2001319 Semantic clinical drug · SCD ● Current RxNorm concept 24 FDA products 61 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2001319
Official nameRoflumilast 0.25 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asroflumilast 250 MCG Oral Tablet
FDA products mapped24
Package NDCs mapped61
Reported Medicaid activity (SDUD)27,120 prescriptions · 45 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Roflumilast: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • That depends on the form you have. The tablet (sold as Daliresp or generic roflumilast) is used to help prevent flare-ups in people with severe COPD tied to chronic bronchitis — it...
  • No — and this is really important. Roflumilast tablets do not open up the airways, so they won't help during a sudden COPD flare or breathing emergency. You need a separate rescue...
  • Can I use the COPD tablet during a sudden breathing attack?
  • This is a real concern worth taking seriously. Roflumilast tablets have been linked to depression, anxiety, trouble sleeping, and in rare cases suicidal thoughts or behavior. It do...
📖 Read our full Roflumilast guide →

🕸️ Concept Web — How Roflumilast 0.25 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Roflumilast 0.25 MG Oral Tablet RxCUI 2001319

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Roflumilast 1091836
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Daliresp 1091840
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Roflumilast Oral Tablet 1091838
    • Roflumilast Oral Product 1156445
    • Roflumilast Pill 1156446
    • Roflumilast Oral Tablet [Daliresp] 1091842
    • Daliresp Oral Product 1167465
    • Daliresp Pill 1167466
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Roflumilast 0.25 MG SCDC · 2001318
  • Roflumilast Oral Tablet SCDF · 1091838
  • Roflumilast Oral Product SCDG · 1156445
  • Roflumilast Pill SCDG · 1156446

Brand-Name Concepts

  • Roflumilast 0.25 MG Oral Tablet [Daliresp] SBD · 2001321
  • Roflumilast 0.25 MG [Daliresp] SBDC · 2001320
  • Roflumilast Oral Tablet [Daliresp] SBDF · 1091842
  • Daliresp Oral Product SBDG · 1167465
  • Daliresp Pill SBDG · 1167466
  • Daliresp BN · 1091840

📦 FDA Products & Package NDCs

24 products · 61 package NDCs
61 package NDCs map to RxCUI 2001319 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
70771-1674-03 30 TABLET in 1 BOTTLE (70771-1674-3) Roflumilast Zydus Lifesciences Limited 2022-10-03
70771-1674-09 90 TABLET in 1 BOTTLE (70771-1674-9) Roflumilast Zydus Lifesciences Limited 2022-10-03
72205-0200-06 10 BLISTER PACK in 1 CARTON (72205-200-06) / 10 TABLET in 1... Roflumilast Novadoz Pharmaceuticals LLC 2022-09-24
72205-0200-30 30 TABLET in 1 BOTTLE (72205-200-30) Roflumilast Novadoz Pharmaceuticals LLC 2022-09-24
72205-0200-90 90 TABLET in 1 BOTTLE (72205-200-90) Roflumilast Novadoz Pharmaceuticals LLC 2022-09-24
72205-0201-24 2 BLISTER PACK in 1 CARTON (72205-201-24) / 10 TABLET in 1... Roflumilast Novadoz Pharmaceuticals LLC 2022-09-24
72205-0201-30 30 TABLET in 1 BOTTLE (72205-201-30) Roflumilast Novadoz Pharmaceuticals LLC 2022-12-21
72205-0201-32 2 BLISTER PACK in 1 CARTON (72205-201-32) / 14 TABLET in 1... Roflumilast Novadoz Pharmaceuticals LLC 2022-09-24
73190-0086-28 2 BLISTER PACK in 1 BOX (73190-086-28) / 14 TABLET in 1 BLI... roflumilast AvKARE 2026-06-24
73190-0087-30 30 TABLET in 1 BOTTLE (73190-087-30) roflumilast AvKARE 2026-06-24
73190-0087-90 90 TABLET in 1 BOTTLE (73190-087-90) roflumilast AvKARE 2026-06-24
Observed labelers: Ascend Laboratories, LLC (9) · Micro Labs Limited (9) · Amici Pharma Inc. (6) · Novadoz Pharmaceuticals LLC (6) · Camber Pharmaceuticals, Inc. (5) · AstraZeneca Pharmaceuticals LP (4) · +6 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.